. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: J Clin Immunol. 2018 Jul 24;38(6):717–726. doi: 10.1007/s10875-018-0534-7

Table 4.

Proportion with granulomas among PIDD patients by age group, MarketScan and USIDNET Registry

	MarketScan Commercial Data (N=247,474)		MarketScan Medicaid Data (n=40,395)		USIDNET Registry (N=4,021)
	No. of PIDD patients	No. (%) with granuloma among PIDD patients	No. of PIDD patients	No. (%) with granuloma among PIDD patients	No. of PIDD patients	No. (%) with granuloma among PIDD patients
Age^a
0–19	86,783	1,051 (1%)	28,530	493 (2%)	2,295	55 (2%)
20–34	41,006	410 (1%)	3,950	52 (1%)	727	56 (8%)
35–44	33,574	417 (1%)	2,631	27 (1%)	356	31 (9%)
45–54	45,807	574 (1%)	2,967	33 (1%)	321	22 (7%)
55–64	40,304	502 (1%)	2,317	19 (1%)	322	13 (4%)

Age based on first PIDD claim during study period for MarketScan data, and age based on age at last visit for USIDNET registry data.